Platelets are a source of vasoactive mediators that regulate vascular tone. Platelets also play a role in intravascular thrombus formation and dynamic coronary constriction that result in myocardial ischemia. However, effects of platelets on myocardial function after ischemia and reperfusion are unknown. In this study, we examined the effects of platelets on myocardial dysfunction caused by ischemia/reperfusion. Buffer-perfused isolated rat hearts, after global ischemia (15 minutes) and reperfusion (10 minutes), developed marked myocardial dysfunction, indicated by a 65 ±4% decrease in the force of cardiac contraction (FCC) and a 26+7% increase in coronary perfusion pressure (CPP). Ischemia/reperfusion was also associated with release of creatine kinase (CK) and ATP metabolites in the coronary effluents. Perfusion of hearts with buffer containing washed rat platelets (3-8x107 cells/ml) protected hearts against dysfunction from ischemia/reperfusion, indicated by minimal changes in CPP (-1±1%) and FCC (-1±3%). Release of CK in the coronary effluent was also reduced, as was the release of ATP metabolites in the platelet-perfused hearts. Perfusion of hearts with serotonin receptor antagonist LY53,857 (10-6 M), thromboxane A2 receptor antagonist SQ29,548 (10-6 M), adenine nucleotide scavenger apyrase (0.4 units/ml), or nitric oxide synthetase inhibitor NG_monomethyl-L-arginine (2x10-4 M) attenuated (p<0.05) the platelet-mediated cardioprotective effects. Perfusion of the hearts with L-arginine (2x10-4 M) instead of platelets also showed modest protective effects on FCC (-4.3±13%), CPP (+18±7%), and CK release. Prolongation of the ischemic period to 30 minutes and reperfusion to 20 minutes also demonstrated marked cardiac dysfunction (FCC, -58±10%; CPP, +36±8%) in buffer-perfused hearts. Perfusion of hearts with platelets in this setting of prolonged ischemialreperfusion also exhibited protective effects on FCC (-24±10%Yo), CPP (+12±6%), and CK release. Thus, platelets protect myocardium from ischemialreperfusion-induced injury, and these protective effects of platelets are evident regardless of the duration of ischemia/reperfusion. Furthermore, these cardioprotective effects of platelets seem to be related to the release of serotonin, thromboxane A2, and adenine nucleotides. These substances most likely elicit release of endothelium-derived relaxing factor, with its attendant tissueprotective effects, from the microvascular endothelium of hearts. (Circulation Research 1993;72:1181-1190 
participate in the regulation of vascular tone and thereby influence the circulatory state in physiological and pathological states. Aggregating platelets relax precontracted blood vessels with intact endothelium by eliciting the release of endothelium-derived relaxing factor (EDRF).2 The release of EDRF was initially attributed to adenine nucleotides derived from aggre-gating platelets.23 Subsequent studies have suggested that TxA2 and serotonin also stimulate EDRF release. 4, 5 In the absence of functional endothelium, platelets cause a marked contraction of blood vessels via TxA2 and serotonin-dependent mechanisms. 2 A number of studies have suggested that platelets participate in the initiation and propagation of myocardial ischemia. For example, platelets accumulate in the narrowed coronary arteries67 as well as in the myocardial tissues8 in animal models of myocardial ischemia. Aggregating platelets also enhance the contraction of blood vessels during anoxia.3 Adhesion of platelets to the subendothelial layers in coronary arteries with atherosclerosis and release of TxA2 and serotonin have been thought of as an initial event in the genesis of occlusive thrombus leading to acute myocardial ischemia.9Y10 Similar platelet deposition occurs at the site of coronary angioplasty and may be the basis of acute occlusion of the affected coronary artery. The major denominator for all these conditions in which platelets seem to play a pathological role is defective endothelial function. A recent study shows that platelets influence cardiac papillary muscle tone depending on the presence of endocardium.1" On the basis of several of these observations,36-10 Vanhoutte and Houston12 first proposed an important interaction between platelets and blood vessel walls in the induction of vasospasm and precipitation of myocardial ischemia.
In animals subjected to coronary artery occlusion followed by reperfusion, myocardial tissues develop tissue injury that has been attributed to the release of free oxygen radicals'3,14 and accumulation of neutrophils in the reperfused tissues.15 16 Although neutrophil accumulation and activation may increase coronary vascular tone17 and the extent of tissue injury,'8 the role of platelets in ischemia/reperfusion-mediated injury remains largely unknown.
The present study was designed to examine the role of platelets in injury caused to the myocardium by a period of prolonged ischemia and reperfusion. These studies were conducted in isolated perfused rat hearts to exclude the confounding effect of other circulating cells.
Materials and Methods Isolated Perfused Heart
Male Sprague-Dawley rats weighing approximately 250 g were anesthetized with xylazine (60 mg/kg) plus ketamine HCl (150 mg/kg) intraperitoneally. Whole blood was drawn from the common carotid artery to harvest platelets. The hearts were rapidly excised and placed in ice-cold Krebs-Henseleit (K-H) buffer composed of (mM) NaCl 118, KCl '19 The hearts were allowed to beat spontaneously and were perfused with K-H buffer at constant flow (4 ml/min). Coronary perfusion pressure was measured via a catheter placed just proximal to the coronary arteries and connected to a Gould Statham P231D pressure transducer. To measure the force of cardiac contraction, the base of the heart was fixed, and a metal hook was attached to the apex of the heart and connected to a force transducer (Kristler Morse, Redmond, Wash.) and a lever system, as described recently by us. 20 The preload before any intervention was kept at 2 g. Both the coronary perfusion pressure and cardiac contractile force were continuously recorded on a four-channel recorder (Astro-Med, Inc., West Warwick, R.I.). Heart rate was calculated from a fast-speed tracing of the cardiac contraction signal.
Platelet Preparation
Rat blood withdrawn from the carotid artery was collected in 3.8% sodium citrate (9:1) and centrifuged at 150g for 10 minutes at 20°C to obtain platelet-rich plasma, which was centrifuged again at 1,000g for 20 minutes. Platelets were washed with Tris-sodium glucose (TSG) buffer composed of (mM) Tris-HCl 15, (CK) release. In the brief ischemia/reperfusion group, hearts were allowed to equilibrate for 20 minutes and were then subjected to 15 minutes of total ischemia (stop perfusion) and 10 minutes of reperfusion. Eleven hearts were perfused with K-H buffer (4 ml/min) and TSG buffer (0.2 ml/min) (used for suspension of platelets) given through a side arm 10 minutes before ischemia and throughout the period of reperfusion. In the platelet-treated group (n=21), hearts were equilibrated for 15 minutes and then perfused with K-H buffer (4 ml/min) and platelets (in a volume of 0.2 ml/min given through a separate side port just proximal to the aortic cannula). The final concentration of platelets was 3 x 107 (n=15) and 8x107 cells/ml (n=6). Ten minutes later, these hearts were subjected to 15 minutes of total ischemia followed by 10 minutes of reperfusion. Platelets were perfused throughout the period of reperfusion.
To investigate the mechanism of the effects of platelets on indexes of myocardial injury, some hearts (n=6 each) were perfused with the ATP/ADP scavenger apyrase (0.4 units/ml), the serotonin (S2) receptor antagonist LY53,857 (10-6 M), the TxA2 receptor antagonist SQ29,548 (10-6 M), or the nitric oxide synthetase inhibitor NG-monomethyl-L-arginine (L-NMMA, 2 x 10`M) along with platelets (3 x 107 cells/ml). These hearts were then subjected to 15 minutes of ischemia followed by 10 minutes of reperfusion. In some experiments (n=6 each), hearts were perfused with apyrase, LY53,857, SQ29,548, and L-NMMA without platelets to determine the direct effects of these agents on cardiac dynamics. Some hearts (n=6) were perfused with nitric oxide precursor L-arginine (2x 10`4 M) instead of platelets and then subjected to 15 minutes of ischemia followed by 10 minutes of reperfusion.
Coronary effluent was collected before ischemia and several times during reperfusion and placed in ice for CK measurement. Coronary effluent was also collected for measurement of ATP metabolites before ischemia and during reperfusion, kept in shaking water bath at 100°C for 5 minutes, and then saved at -4°C. Effluents were also collected for measurement of 6-ketoprostaglandin F,a (6-keto-PGF1a) release. After completion of the experiment, hearts were saved at -70°C for subsequent measurement of CK; some hearts (n=6) perfused with buffer or platelets were perfused with Trump-McDowell fixative for 5 minutes and saved in the fixative for subsequent electron microscopic examination.
To determine the effects of platelets on prolonged myocardial ischemia and reperfusion, another group of hearts (n = 6) were perfused with buffer or platelets and subjected to 30 minutes of ischemia followed by 20 minutes of reperfusion. 
CK

Measurement ofATP Metabolites
Coronary effluent samples were assayed for hypoxanthine, inosine, and adenosine by reverse-phase highperformance liquid chromatography (HPLC) according to the method used by Hartwick et Buffer-perfused and platelet-perfused hearts were subjected to transmission electron microscopy (TEM) as described earlier. 23 Briefly, tissue samples were taken from the endocardial and epicardial regions of the lefti ventricle and cut into 1-mm cubes fixed in 3% buffered glutaraldehyde for TEM. Tissues were allowed to fix for 1-6 hours and then were transferred to 1% osmium tetroxide in 0.1 M cacodylate buffer, dehydrated, and embedded in Epon. The artifact-free areas with the most capillaries were selected for ultrathin section cutting and examined with Zeiss 1091 GF electron microscope.
-heptenoic acid,4 the TxA2-endoperoxide receptor antagonist SQ29,548, was a gift of Squibb, Princeton, N.J. 4-Isopropyl-7-methyl-9-(2-hydroxy-1-methylpropoxycarbonyl)-4,6,6a,7,8,9,10,10a-octahydroindolo(4,3-FD)quinoline maleate,24 the S2 receptor antagonist LY53,857, was obtained from Eli Lilly and Co., Indianapolis, Ind. All other supplies were purchased from Sigma.
Statistical Analysis
Changes in coronary perfusion pressure, force of cardiac contraction, and heart rate are expressed as percent increase or decrease from preischemic values.
All values are expressed as mean +±SEM. One-way and two-way analyses of variance were used to evaluate the statistical significance. A value of p<0.05 was considered significant.
Results
Cardiac Dynamics During Ischemia and Reperfusion
In the control continuously perfused hearts observed for 45 minutes, there were only minimal changes in coronary perfusion pressure, the force of cardiac contraction, and heart rate. In hearts subjected to a brief period of global ischemia (15 minutes) followed by reperfusion (10 minutes), the force of cardiac contraction decreased 65+±4% (p<O.001 versus the control group), coronary perfusion pressure increased 26+7% (p<O.OO1), and the heart rate decreased 6+5% (p=NS) after 10 minutes of reperfusion (Table 1 ). These changes in the force of cardiac contraction and coronary perfusion pressure reflect marked myocardial dysfunction.
Hearts perfused with platelets demonstrated a modest (19+4%), but consistent, increase in the force of cardiac contraction, without any change in coronary perfusion pressure or heart rate. After 15 minutes of ischemia and 10 minutes of reperfusion, the force of cardiac contraction, coronary perfusion pressure, and heart rate were unchanged from values just before the onset of ischemia. However, the values of coronary perfusion pressure and the force of cardiac contraction after ischemia and reperfusion were markedly (p<O.OO1) different from those in hearts perfused with buffer alone (Table 1) . Thus, the Representative examples of cardiac dynamics in hearts subjected to ischemia and reperfusion perfused with and without platelets are shown in Figure 1 , and data from multiple experiments are presented in Figure  2 . The cardioprotective effects of platelets were observed at both concentrations (3 Figure 2 ). Since rats in the 15-minute ischemia group and 30-minute ischemia group came from different batches, the data between these two groups are not comparable.
Mechanism of Cardioprotective Effects of Platelets
Perfusion of hearts with the S2 receptor antagonist LY53,857, the TxA2 receptor antagonist SQ29,548, or the ATP/ADP scavenger apyrase had no effect on cardiac dynamics. However, perfusion of hearts with these agents along with platelets attenuated the platelet-mediated protective effects on cardiac dynamics after 15 minutes of ischemia and 10 minutes of reperfusion. Perfusion of hearts with L-NMMA resulted in a minimal increase of coronary perfusion pressure (8±2%, p=NS). Subsequent perfusion of these L-NMMA-treated hearts with platelets failed to show cardioprotection from ischemia/reperfusion-mediated dysfunction (Figures 3 and 4) .
Perfusion of hearts with L-arginine instead of platelets resulted in a modest increase in the force of cardiac contraction (21±6%) without any change on coronary perfusion pressure and heart rate. After 15 minutes of ischemia followed by 10 Figure 5 ). In groups of hearts subjected to prolonged ischemia and reperfusion, perfusion with platelets showed the same protective effect on CK release (data not shown). Figure 6 ).
PGI2 Release in Coronary Effluents
Fifteen minutes of ischemia and 10 minutes of reperfusion caused marked release of PGI2 as identified by 6-keto-PGF,a in the coronary effluents during reperfusion. Coronary effluents of platelet-perfused hearts subjected to ischemia and reperfusion also revealed release of PG12; however, the magnitude of PGI2 release in coronary effluents was similar whether hearts were perfused with or without platelets (Figure 7 ).
Release ofATP Metabolites in Coronary Effluents
There was minimal release of ATP metabolites in the coronary effluents of hearts perfused continuously with buffer. Fifteen minutes of ischemia resulted in marked release of hypoxanthine, inosine, and adenosine in the coronary effluents during reperfusion. The maximal release was seen during the first 2 minutes of reperfusion. The release of ATP metabolites was still present at 10 minutes of reperfusion, although at a lower rate (Table 2 ). In platelet-treated hearts subjected to 15 minutes of total ischemia, peak levels of ATP metabolites were not different from those observed in the hearts perfused with buffer alone. However, the value of all ATP metabolites at 10 minutes of reperfusion was lower, indicating a shorter duration of release of aden- osine in hearts perfused with platelets and subjected to ischemia and reperfusion. Nevertheless, of all ATP metabolites measured, only the adenosine value at 10 minutes of reperfusion was significantly (p<0.05) lower than that in the effluents of hearts perfused with buffer alone (Table 2) .
Transmission Electron Microscopy
After TEM of hearts subjected to 15 minutes of ischemia and 10 minutes of reperfusion, aggregated platelets were observed in almost all capillaries in the platelet-perfused hearts but not in buffer-perfused hearts. No difference of myocardial injury could be discerned from TEM of the myocardium. The endothelial lining of all capillaries seemed to be intact (Figure 8 ).
Discussion
In this study of isolated rat hearts, global ischemia followed by reperfusion resulted in a marked decrease in the force of cardiac contraction accompanied by increase in coronary perfusion pressure. These alterations in cardiac dynamics indicate myocardial dysfunction after ischemia and reperfusion. The cardiac dysfunction was more pronounced after prolonged (versus brief) periods of ischemia and reperfusion, although the changes in cardiac dynamics were qualitatively similar.
Biochemical evidence of cardiac injury was evident from release of CK and ATP metabolites in the coronary effluents. The novel aspect of the present study is that perfusion of hearts with platelets provided significant protection against myocardial dysfunction caused by ischemia and reperfusion, regardless of the duration of ischemia and reperfusion. The biochemical indexes also showed reduction in cardiac injury. In addition, the adenine nucleotide scavenger apyrase, the S2 receptor antagonist LY53,857, and the TxA2 receptor antagonist SQ29,548 all attenuated the platelet-mediated protection from ischemia/reperfusion-induced cardiac dysfunction and injury. It is noteworthy that neither apyrase, LY53,857, nor SQ29,548 had a direct effect on cardiac dynamics. These observations indicate that platelets protect myocardium from ischemia/reperfusion-induced dysfunction and injury and that these protective effects of platelets are related to release of TxA2, serotonin, and adenine nucleotides during interaction between platelets and coronary vasculature.
Platelet aggregation has been observed in the narrowed coronary arteries6,7 as well as in ischemic/reperfused myocardium.A Antiplatelet agents such as aspirin, TxA2 synthetase, receptor antagonists, and serotonin receptor antagonists have all been shown to decrease intracoronary platelet deposition and to limit myocardial infarct size in experimental models of myocardial ischemia. 25 29 On the basis of these studies, it has been generally believed that platelets exert a detrimental effect on myocardial ischemic injury via release.of TxA2 and serotonin.30131 However, the present studies indicate that platelets may play an entirely different and cardioprotective role in reperfusion-induced cardiac dysfunction and injury.
We determined cardiac injury by measurement of CK in the coronary effluents as well as residual CK in the myocardium. CK determination has been previously established to reflect the extent of cardiac injury. 32 We found diminished CK release in the coronary effluents at; Nt~~~~W FIGURE 8. Transmission electron micrographs of buffer-perfused heart (left panel) and platelet-perfused heart (right panel) subjected to ischemia (15 minutes) and reperfusion (10 minutes). Note the absence ofplatelet aggregates in the buffer-perfused hearts (display magnification x3,000; print magnification, x6,675). In contrast, the platelet-perfused heart shows platelet aggregate in the capillary (display magnification, x3,000; print magnification, x6,675). Note that the endothelial lining is intact in both myocardial sections and that there is no anatomic evidence of myocardial injury.
.. J7, and greater residual CK in the hearts perfused with platelets. These observations suggest that cardiac injury is reduced in hearts perfused with platelets before and after global ischemia.
Release of ATP metabolites has been thought to reflect ATP depletion during myocardial injury.33 In our studies, the levels of hypoxanthine, inosine, or adenosine were markedly elevated in the coronary effluents during reperfusion, when the release of ATP metabolites is maximal. 33 The peak values of ATP metabolites were similar in hearts perfused with or without platelets (Table 2) . However, at 10 minutes of reperfusion, the release of all ATP metabolites was lower in the plateletperfused hearts than in the buffer-perfused hearts, although only the value for adenosine was significantly lower. The failure to achieve significance with lower values for inosine or hypoxanthine probably reflects a type II error. Nonetheless, the sum of all ATP metabolites was significantly lower in the platelet-perfused (versus buffer-perfused) hearts. The observation of less pronounced ATP depletion in platelet-perfused hearts also suggests a lesser degree of ischemic injury. Although adenosine in large amounts given by intracoronary route is thought to be cardioprotective during myocardial ischemia and reperfusion,34 the concentration of adenosine in the myocardium is too low to provide cardioprotection in the present studies.
TEM showed aggregated platelets in most capillaries of platelet-perfused hearts but not in buffer-perfused hearts. However, perfusion of hearts with platelets had no effect on cardiac dynamics before ischemia except for a modest increase (19±4%) cells/ml) and observed that platelets caused contraction of the papillary muscle, which was greater in papillary muscles with intact endocardium. Our study shows that perfusion of hearts with platelets increases the force of cardiac contraction modestly before ischemia but markedly prevents the decrease in the force of cardiac contraction after ischemia and reperfusion. It is possible that the rapid recovery in the force of cardiac contraction after myocardial ischemia relates to the direct inotropic effect of platelets on myocardium. Platelets release several substances, including serotonin, TxA2, adenine nucleotides, and calcium.1'42 Both serotonin and ATP cause contraction of isolated cardiac tissues in serotonin and other platelet-released substances43'44 and possible changes in calcium concentration and pH during transit of platelets through the heart probably account for the platelet-mediated recovery in the force of cardiac contraction soon after ischemia and reperfusion. This hypothesis is supported by our observations that the S2 receptor antagonist LY53,857, the TxA2 receptor antagonist SQ29,548, and the ATP/ADP scavenger apyrase all attenuated the myocardial protective effects of platelets.
Adenine nucleotides, TxA2 endoperoxides, and serotonin have all been shown to induce the release of EDRF from blood vessels with intact endothelium. 245 We hypothesize that the release of large amounts of EDRF from the coronary vascular endothelium after interaction with platelets most likely accounts for the observed effects of platelets during ischemia and reperfusion. Direct evidence for this hypothesis comes from our experiments in isolated hearts perfused with L-arginine, a precursor of EDRF, and subjected to ischemia and reperfusion. Perfusion of hearts with L-arginine provided a modest, but definite, protection against ischemia/reperfusion-mediated cardiac dysfunction. In addition, in experiments in which hearts were pretreated with L-NMMA, an inhibitor of EDRF synthesis, and then perfused with platelets, the cardioprotective effects of platelets were abolished. These studies clearly demonstrate that cardioprotection by platelets against reperfusion injury relates to release of EDRF. EDRF has indeed been thought of as a cardioprotective factor, 45 and free oxygen radicals.4648 Whereas leukocytes exert cardiosuppressive effects, the demonstration of the cardioprotection by platelets in the present study suggests that platelets may have a role in counteracting some of the noxious effects of leukocytes in the setting of myocardial reperfusion.
In summary, our studies indicate that platelets exert cardioprotective effects when isolated rat hearts are subjected to global ischemia and reperfusion. The cardioprotective effects, which are attenuated by apyrase, SQ29,548, LY53,857, and L-NMMA, seem to be related to the release of EDRF in the microvasculature in response to adenine nucleotides, TxA2, and serotonin. Accordingly, apyrase, TxA2, and S2 receptor antagonists readily attenuate the beneficial effects of platelets on reperfused cardiac tissues. However, it needs to be recognized that the beneficial effects of platelets described in the study relate to the blood-free model of isolated hearts subjected to ischemia and reperfusion. In clinical situations in which the coronary arteries may have long-standing atherosclerosis53 or in which the endothelium is injured, especially after fissuring or ulceration of the atherosclerotic plaque, the effects of circulating platelets may be different. 54, 55 
